AIP · Arteris, Inc.

Current Thesis

Arteris’ chiplet-interconnect story now rests on a repair case: a weekly recovery above the former $26 threshold, supported by delivery against its August revenue guidance, before the market loses the April reference near $19.56. The September 18, 2026 adjusted close was $22.30; the earlier $26 invalidation has already occurred and remains a failed call, not an untested condition.

The material development since the September 6 note is the September 15 introduction of FlexGen Multi-Die, which extends communication between components across separate pieces of silicon. Arteris announced availability to early-access partners and strategic customers, but disclosed no product-specific revenue or contract value. That adds a commercial proposition without quantifying its earnings contribution. Company announcement, September 15

As an interpretation of the price evidence, the narrative is dead in its previous momentum form — the September 18 close remained below the failed $26 threshold and 54.1% below the supplied 52-week high. The narrower repair case has low conviction: it requires a weekly close above $26 and third-quarter revenue of at least the August guidance floor of $24 million, with full-year guidance retained, before a weekly close below $19.56.

Bullish and bearish views on Arteris, Inc.

The model's bull view on Arteris, Inc. (AIP), in brief: Revenue supports the operating case. The August 6, 2026 results reported second-quarter revenue of $24.13 million, up 46% year over year, and raised full-year revenue guidance to $95–98 million. Those are reported results and management guidance, respectively. Second-quarter… The bear view: The earlier failure remains unresolved. The September 18, 2026 adjusted close of $22.30 remained below the prior $26 threshold, while the supplied three-month price change was negative 49.9%. The September product release has not yet been accompanied by recovery of that… Both cases follow in full.

Bull Case

• Revenue supports the operating case. The August 6, 2026 results reported second-quarter revenue of $24.13 million, up 46% year over year, and raised full-year revenue guidance to $95–98 million. Those are reported results and management guidance, respectively. Second-quarter release
• Royalties provide a separate test. The August 6 release reported trailing-twelve-month variable royalties of $8.6 million, up 65% year over year, alongside remaining performance obligations of $135 million, up 36%. These support the licensing-and-royalty case independently of the September product announcement. Second-quarter release
• Chiplet offering gains named support. The September 15 announcement included statements from AMD and Socionext about Arteris’ multi-die technology. This is evidence of customer engagement; the release does not establish the revenue attributable to those statements. Product announcement

Bear Case

• The earlier failure remains unresolved. The September 18, 2026 adjusted close of $22.30 remained below the prior $26 threshold, while the supplied three-month price change was negative 49.9%. The September product release has not yet been accompanied by recovery of that threshold.
• Growth still accompanies accounting losses. The August 6 results reported a second-quarter net loss under generally accepted accounting principles of $14.07 million, or $0.30 per share. Management also guided to a full-year adjusted operating loss of $7–10 million. Second-quarter release
• Publicity does not measure participation. Arteris’ newsroom lists coverage of the chiplet announcement by Design & Reuse and Embedded Computing Design on September 15, and Yahoo Finance on September 16. These references cluster around the same announcement; they do not measure independent investor demand or retail crowding. Company newsroom

Setup & Price Structure

The supplied September 18, 2026 market snapshot records a $22.30 adjusted close and a 14-period relative strength index of 51.7. The September 6 published note recorded a September 4 close of $21.37 and an index reading of 20.3. Those observations show a higher reference close and a recovered momentum reading, but the sample is too small to establish a durable base or expanding participation.

The former $26 invalidation threshold is now the repair test. The April market reference near $19.56, identified in the September 6 coverage, supplies the lower boundary for this narrower case. Neither level is a newly observed September support shelf. Current moving-average readings, short interest and fund-flow measurements are missing, so distance above a rising average and positioning concentration cannot be established.

The September 15 product launch and September 16 conference appearance preceded the September 18 close, but that sequence alone does not establish that either event caused the price recovery.

Catalyst Calendar (next 30 days)

• 2026-09-20 through 2026-10-20: No company-confirmed event in this window appears on the investor-relations calendar checked September 20. The calendar places the September 16 Piper Sandler Growth Frontiers Conference among past events; it is no longer an upcoming catalyst. Company calendar
• ~2026-11-04, unconfirmed estimate: The earlier coverage placed third-quarter results around this date; the current company calendar does not confirm it. This later report is the substantive test of the $24–25 million quarterly revenue guidance and $95–98 million full-year guidance issued August 6. The date remains provisional. Company calendar

What Would Change Our Mind

Loss of the April reference would end the repair case: a weekly close below $19.56 is the price invalidation. This does not reverse the already-triggered $26 condition documented in the September 6 note.

The operating case would also break if third-quarter revenue fell below the $24 million floor issued August 6, or if management reduced the $95–98 million full-year revenue range. Conversely, a weekly close above $26 together with delivery against those revenue conditions would satisfy the narrower repair case. A product announcement without those observations does not satisfy it.

Correlation Notes

This remains a single-name setup. The September 15 announcement connects Arteris’ network-on-chip intellectual property to artificial intelligence and chiplet development, but customer statements do not establish that its shares track AMD or the broader semiconductor market. Product announcement

The September 18 evidence contains no matched benchmark-return series. It therefore supports neither a measured correlation nor an attribution of the three-month decline to sector flows rather than company-specific repricing.